According to these evidences, the evaluation of lncRNA expression could allow to select, among all c-KIT-mutated GIST patients eligible to receive first-line therapy with imatinib, those who could really benefit from this treatment reserving another more effective therapy to the others, with interesting implications for their clinical management. This evidence concerns the gene KIT and gastrointestinal stromal tumor.